It is with great pleasure and honor that we announce that Masco Group has signed the acquisition of a majority shareholding of BCD Engineering Ltd, active since 1983 in the engineering and manufacturing of high purity process systems worldwide for the Pharmaceutical, Biotechnology, Food & Beverage and Chemical industries. They have particular expertise in Product Formulation, Clean in Place, Clean Utilities and Thermal Treatment technologies. Based out of Charleville-Cork Ireland, BCD employs about 250 highly skilled people.
This acquisition, pending CCPC Ireland approval, will strengthen Masco Group’s leadership in both the segment for Olsa liquid process (Pharma plus Food & Beverage) technologies as well as for Stilmas clean utilities, liquid processing, super skids and turn-key manufacturing systems for the global markets.
For more on their expertise, capabilities and industries served visit www.bcd.ie
Join Olsa at the 5th edition of the APIC Arab Pharmaceutical Industry Congress 2019 organized by Akhnaton Trading & Representation on 8-9 October at the Hilton Heliopolis in Cairo, Egypt.
Our experts will give lectures on Cleaning in Place (Procedures, systems and customization), super skids for sterile manufacturing and modular approach.
To register: https://bit.ly/2nbVP9A
The APIC is designed to provide an innovative and comprehensive overview of the latest developments in pharmaceutical industry. The event offers a platform for professionals to share knowledge, network, and discuss trends in the pharmaceutical industry with the pioneers in the field.
The three main streams (Scientific Lectures) will be: – Production, Bio pharmaceuticals & productivity. Quality assurance & Regulation Compliance. Research & Development.
Olsa will take part in the annual event CPhI Worldwide 2019 in Frankfurt.
Find our experts in the PMEC area, hall 11, booth 110B71.
The world’s largest pharmaceutical exhibition, CPhI Worldwide houses six zones representing each stage of the pharmaceutical supply chain – from APIs, machinery and packaging to outsourcing and biopharmaceuticals. Uniting over 45,000 visiting attendees and 2,500 international exhibitors, CPhI Worldwide is the place to network and source cost-effective pharma solutions from all over the world – in just 3 days, under one roof.
See the official Event Guide Preview.
The history of plasma fractionation began in WWII, with the need to develop blood serum products to help soldiers suffering from shock and burns.
Nowadays, Olsa is helping the fight against important diseases by designing and manufacturing plasma fractionation systems.
Check out this relevant and insightful article by Roberto Vassena, Olsa’s director of commercial operations, on the implementation of an impressive plasma fractionation system in a CIS country.
Make sure to follow our new and improved Linkedin page for Olsa’s latest news and content:
Stilmas Expands its North American Operations with the Acquisition of Mar Cor Purification’s High Purity Water Business Based in Burlington Ontario, Canada
Milan, Italy November 1, 2018/PRNewswire/ — Stilmas is pleased to announce that effective November 1, 2018 it has acquired the assets of Mar Cor Purification’s High Purity Water Business based in Burlington, Ontario, Canada. The new company will be named Stilmas Americas, and will serve the North American market, expanding the Mar Cor Purification High Purity water portfolio of products. Mar Cor Purification currently manufactures a line of water purification equipment platforms that are compliant with the current USP and EU Purified Water (PW) and Water for Injection (WFI) standards. They specialize in standard and custom engineered turn-key systems for the Pharmaceutical, Biotech, Cosmetic and Semi-Conductor markets.
The Masco Group, with its Companies Stilmas, Olsa and DOC, is a global market leader in the field of pure water technologies and systems for the pharmaceutical and cosmetic industry. The Masco Group is headquartered in Milan, Italy, with operations in France, China, Russia and USA. Stilmas manufactures state of the art Pharmaceutical Quality Water Systems that include Multiple Effect Stills, Vapor Compression Stills and Pure Steam Generators along with other standard products.
Alberto Borella – CEO Masco Group: “We have found in the High Purity Business Line of Mar Cor Purification the perfect complement of products and competencies to successfully carry out our vision and grow our business. Stilmas Americas will become the reference clean media provider in North America”.
Benjamin Roczniak – President Stilmas Americas: “We are excited that we now have a complete portfolio of State of the Art Biopharma water products that will allow us to provide our customers with complex turnkey solutions”.
Stilmas Americas will be the hub for selling, engineering, manufacturing and servicing Stilmas equipment in North America, becoming a unique player to offer a complete range of pure media technologies in the North American market.
For further information, visit Stilmas website at www.stilmas.com.
Masco-Group has retained Industrial Investment Company of
RAG-Foundation as long-term majority shareholder
The Masco Group with its business units Stilmas, Olsa and DOC is a global market leader in the field of pure water technologies and systems for the pharmaceutical and cosmetic industry.
Masco Group has a unique track record and experience of more than 100 years in Pure Water Systems as well as complete solutions for liquid production pharmaceutical plants, including product preparation areas. Moreover, the group offers a wide range of services related to the validation in the pharmaceutical and cosmetic industry. The company has the honor to be a reliable and innovative business partner for the leading global and local pharmaceutical and cosmetic companies.
Taking into account the excellent growth opportunities regarding regional expansion, automation solutions as well as larger turnkey projects including balance of plant systems the ownership family has decided to team up with an experienced business partner enabling Masco not only to keep the traditional values of the company and their independence but also to combine it with the highly interesting knowledge and competencies of a global industrial network.
“We are excited to announce this strategic collaboration with RAG Investment Company which will support the acceleration of our business on the global scale. Our new strategic investor will allow Masco to maintain the entrepreneurial spirit and ensure that our business model, network of customers, partnerships and objectives are even reinforced to achieve new ambitious targets,” said Alberto Borella, CEO Masco Group.
Jürgen Wild the Managing Partner of RAG Investment Company:
“Masco Group is a flagship of northern Italy’s high tech industry which started very early in time to become a global player serving customers around the world. Their innovation spirit was always looking for best-in-class solutions satisfying the highest standards of its superb customer base. In addition, the company also developed forward its offering to customers from products to turnkey solutions. With the unique combination of in-house development, production, validation and service Masco Group is the recognized market leader. We are privileged to become the business partner of choice and will commit ourselves to the future success of this outstanding company.”
The Borella family maintains committed to Masco as shareholder and as board members in the management of the group.
Dr.Eng. Alberto BORELLA
CEO Masco Group
Masco Group is pleased to invite you to our Seminar, organized in collaboration with Melapack Kft. Process division dedicated to the Pharmaceutical and Cosmetic Industries.
Through the several lectures presented, it will be provided an update about the latest regulatory requirements and an anticipation about the ones that will become effective starting from 2017.
Moreover the latest technological trends related to the manufacturing of pharmaceutical and cosmetic finished products like sterile solutions, suspension and ointments will be shown through specific case studies coming from our experience.
The last part of the Seminar will be dedicated to the Quality matter and it will cover the qualification and validation aspects of material, equipment and containers in contact with the pharmaceutical drug formulation.
Entry is free, however places are limited, please register in advance to confirm your attendance.
For any additional information regarding the participation please fill the form below